Protecting people against leprosy: Chemoprophylaxis and immunoprophylaxis.

Printer-friendly version
TítuloProtecting people against leprosy: Chemoprophylaxis and immunoprophylaxis.
Tipo de PublicaciónJournal Article
AutoresRichardus JH, Oskam L
Abbrev. JournalClin Dermatol
RevistaClinics in Dermatology
Año de Publicacion2015
Volume33
Issue1
Pagination19 - 25
Idioma de Publicacióneng
Resumen

Elimination of leprosy cannot be achieved by multidrug therapy alone, and new tools are needed to prevent leprosy. A randomized controlled trial with chemoprophylaxis for contacts of leprosy patients using a single dose of rifampicin (SDR) has shown an overall protective effect of approximately 60%, effective in the first 2 years after the intervention. When a contact who previously received bacillus Calmette-Guérin (BCG) vaccination also receives SDR, the protective effect is additive, approximating 80%. Vaccine trials have been conducted with BCG, often in combination with Mycobacterium leprae or related Mycobacterium vaccines as immunoprophylaxis for contacts of leprosy patients, with BCG giving the best results. Meta-analysis shows that the protective effect of BCG vaccination is larger in observational studies than in trials, 60% versus 41%, and is higher among contacts of leprosy patients than among the general population, 68% versus 53%. We believe that a future leprosy control strategy should include contact management, consisting of a contact survey, at which time preventive interventions could be added, such as chemoprophylaxis and immunoprophylaxis. Modeling studies have shown that both interventions will lower the incidence of leprosy in the population. Implementation studies of such contact-based strategy are now called for.

PubMed URL

http://www.ncbi.nlm.nih.gov/pubmed/25432807

DOI10.1016/j.clindermatol.2014.07.009
Shelf markRICHARDUS 2015